April 2002 (v02-n04)
 |
|
- Main Story - pgs. 1-16 Esperion Corporation (NASDAQ:ESPR)
- Macro Market Commentary - pgs. 17-18
- NIBM Notes - pg. 19
- NIBM Model Portfolio & Updates - pgs. 20-23
|
 |
|
| This month's Main Story is on
Esperion Corporation. Esperion is a leading company in pursuit of Reverse Lipid Transport
(RLT), the process whereby the body uses HDL -- "good" cholesterol" -- to
eliminate bad cholesterol and the plaques that can form in blood vessels. The company has
several promising products with the capability of reaching a few billion dollars in annual
sales by the end of this decade. |
|
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - Esperion
- Introduction
- Table: Basic Facts
- Esperion and the NIBM Model Portfolio
- Disclosure
The race for HDL efficacy
- Table: Selected cholesterol therapies (in millions of USD)
- LDL lowering not the whole solution
- The NIH weighs in
- Sidebar: ATP-3's effect on drug sales
Reverse Lipid Transport and HDL science
- Table: Major particle players
- Atherosclerosis
- Reverse Lipid Transport (RLT)
- Hypothesizing HDL therapies
- Key take-aways
Esperion's Products
- Table: Esperion Products
- ETC-588 (LUV)
- ETC-216 (AIM)
- ETC-642 (RLT Peptide)
- ESP-31015 (Oral HDL Wonder Drug)
- ETC-276 (Pro Apo-a1)
MRI/IVUS technologies
Competitive landscape
- Square pegs in round holes
- Table:Effect on HDL of popular drugs
- CETP inhibitors
- Fibrates
- Niacin/Kos Pharmaceuticals
- Avasimibe/ACAT inhibitors
Partnering
Operations/Management
Table: Upcoming milestones
What Can Go Wrong
- Macro Market Commentary
-
- NIBM Notes
- NIBM Model Portfolio and Updates
- Genta
- Dendreon
- AltaRex
- Targeted Genetics
- Nabi Biopharmaceuticals
- PAREXEL
- Titan Pharmaceuticals
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
